Merkel cell carcinoma

By Abdulhadi Jfri, MD, MSc, FRCPC, FAAD, and Catherine Pisano, MD, FAAD

Merkel cell	Causes	Location
Receptor of light touch in the basal layer	Merkel cell polyomavirus 80%UV signature mutations 20%	Head and neck (most common)ExtremitiesButtock




Abdulhadi Jfri, MD, MSc, FRCPC, FAAD, is a Complex Medical Dermatology Fellow

at Brigham and Women's Hospital Dana-Farber Cancer Institute, Harvard Medical School.



Catherine
Pisano, MD,
FAAD, is a
Cutaneous Oncology
Fellow at Brigham
and Women's
Hospital, Dana-Farber
Cancer Institute,
Harvard Medical
School.



Clinical ddx

Basal cell carcinoma, squamous cell carcinoma, amelanotic melanoma, cutaneous lymphoma, cutaneous metastasis, angiosarcoma, dermatofibrosarcoma protuberans, keratoacanthoma, neuroblastoma, adnexal tumors, and neural tumors (neuroma, schwannoma).

Merkel cell carcinoma

By Abdulhadi Jfri, MD, MSc, FRCPC, FAAD, and Catherine Pisano, MD, FAAD

AJCC 8th T staging				
Tis:	In situ			
T1	≤ 2 cm			
T2	> 2 cm ≤ 5 cm			
Т3	> 5 cm			
T4	Muscle, fascia, cartilage, or bone			

AJCC 8th clinical (cTNM)					
St.	Т	N	М		
0	Tis	cN0	M0		
I	T1	cN0	MO		
IIA	T2-T3	cN0	M0		
IIB	T4	cN0	MO		
Ш	T0-T4	cN1-3	MO		
IV	T0-T4	Any N	M1		

AJCC 8th pathological (MNTq) St. Т Ν M 0 Tis pN0 M0 I T1 pN0 M0 pN0 IIA T2-T3 M0 IIB T4 pN0 M0 IIIA T1-T4 N1a(sn) M0 T0 N₁b IIIB T1-T4 N1b-3 M0 IV T0-T4 Any N M1

Prognosis: 5-year overall survival (OS):

Local: 51% Nodal 35% Distant 14%

Poor prognostic factors:


Clinical

Size: > 2 cm
Location: head & neck
Male
Immunosuppression

Path

Increased P63
Sheet like pattern
Negative CK20
Negative Merkel
polyomavirus

Management



- Surgical excision with 1-2 cm margin
- Sentinel lymph node biopsy
- Radiation of the Merkel site and draining node basin if needed
- PET CT scan or CT chest/abdomen/ pelvis to search for distant metastasis

Patient not a
surgical candidate?
Radiation alone

(Merkel is very radiosensitive)

Patient has metastatic Merkel?

Immunotherapies (pembrolizumab, nivolumab, or avelumab)

Markers to follow-up response to treatment

- MCPyV oncoprotein antibodies (AMERK) at baseline, if positive, serial titers may be drawn to monitor response to treatment and help to predict recurrent disease/increased tumor burden
- Circulating tumor DNA (ctDNA) (FDA approved for monitoring colon cancer post-surgery, under investigation in MCC)

Special thanks to **Manisha Thakuria**, **MD**, **FAAD**, director of the Merkel Cell Carcinoma Clinic Center of Excellence at Dana-Farber Cancer Institute, for reviewing this Boards Fodder chart.

References:

- 1. Bolognia. Dermatology 4th edition
- 2. Fitzpatrick's dermatology 9th edition.
- 3. Kathleen Coggshall, Tiffany L. Tello, Jeffrey P. North, et al. Merkel cell carcinoma: An update and review Pathogenesis, diagnosis, and staging. *J Am Acad Dermatol.* 2018 Mar;78(3):433-442. doi: 10.1016/j.jaad.2017.12.001. Epub 2017 Dec 9.
- 4. NCCN Clinical Practice Guidelines in Oncology. Merkel cell carcinoma. Version 1. 2021-Feb 18, 2021.

Boards bonus!



In addition to this

issue's Boards Fodder. download two new online Boards Fodder charts. Paisley tie differential diagnoses, by Sujitha Yadlapati, MD, and Thomas Davis, MD, FAAD: and **Graft-versus-host** disease (GVHD), by Abdulhadi Jfri, MD, MSc, FRCPC, FAAD, and Rachel Meltzer, MD, MPH, FAAD. Check out the archives at www.aad. org/boardsfodder.

Got Boards?



AAD welcomes new Boards Fodder chart ideas. View the Boards Fodder guidelines for submission at www. aad.org/member/ publications/more/ dir. Contact DW Directions Editor Dean Monti at